|
|
||||||||
AJP - Regulatory, Integrative and Comparative Physiology, Vol 259, Issue 1 84-R89, Copyright © 1990 by American Physiological Society
ARTICLES |
Z. Abassi, A. Haramati, A. Hoffman, J. C. Burnett Jr and J. Winaver
Rappaport Institute for Research in the Medical Sciences, Faculty of Medicine, Technion, Haifa, Israel.
Increased activity of the renin-angiotensin system is thought to play a major role in the pathogenesis of salt retention and edema formation in congestive heart failure. The present study evaluates the effects of chronic inhibition of angiotensin-converting enzyme on the response to infusion of exogenous atrial natriuretic factor (ANF) in salt-retaining rats with chronic arteriovenous (a-v) fistula, an experimental model of high-output congestive heart failure. Administration of ANF in incremental doses (5-50 micrograms.kg-1.h-1) to Inactin-anesthetized, sham-operated control rats resulted in dose-dependent increases in urine flow, sodium excretion, and glomerular filtration rate, and significant decreases in mean arterial blood pressure. These effects of atrial peptide were markedly attenuated in salt-retaining rats with a-v fistula. However, chronic oral treatment with the angiotensin-converting-enzyme inhibitor enalapril restored the natriuretic response of sodium-retaining rats with a-v fistula to high doses of ANF. At a dose of 50 micrograms.kg-1.h-1, fractional excretion of Na (FENa) in a-v fistula rats given enalapril was 4.0 +/- 0.5%, which was significantly greater than that in a-v fistula rats without enalapril (0.5 +/- 0.4%, P less than 0.05) and not different from the response in sham-control rats (4.9 +/- 0.7%). The improvement in the natriuretic response after enalapril was not associated with a significant increase in GFR and occurred despite a decrease in mean arterial pressure. Moreover, chronic enalapril treatment did not significantly alter the plasma levels of immunoreactive ANF in either the sham controls or in the rats with a-v fistula.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
Z. S. Azzam, Y. Adir, L. Welch, J. Chen, J. Winaver, P. Factor, N. Krivoy, A. Hoffman, J. I. Sznajder, and Z. Abassi Alveolar fluid reabsorption is increased in rats with compensated heart failure Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L1094 - L1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. A. Abassi, A. Yahia, S. Zeid, T. Karram, E. Golomb, J. Winaver, and A. Hoffman Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H722 - H728. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Chen, J. A. Schirger, W. L. Chau, M. Jougasaki, O. Lisy, M. M. Redfield, P. T. Barclay, and J. C. Burnett Jr Renal Response to Acute Neutral Endopeptidase Inhibition in Mild and Severe Experimental Heart Failure Circulation, December 14, 1999; 100(24): 2443 - 2448. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Brodsky, K. Gurbanov, Z. Abassi, A. Hoffman, R. R. Ruffolo Jr, G. Z. Feuerstein, and J. Winaver Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure Hypertension, October 1, 1998; 32(4): 746 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Abassi, K. Gurbanov, I. Rubinstein, O. S. Better, A. Hoffman, and J. Winaver Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide Am J Physiol Renal Physiol, April 1, 1998; 274(4): F766 - F774. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. A. Abassi, K. Gurbanov, S. E. Mulroney, C. Potlog, T. J. Opgenorth, A. Hoffman, A. Haramati, and J. Winaver Impaired Nitric Oxide–Mediated Renal Vasodilation in Rats With Experimental Heart Failure : Role of Angiotensin II Circulation, November 18, 1997; 96(10): 3655 - 3664. [Abstract] [Full Text] |
||||
![]() |
Z. A. Abassi, S. Kotob, E. Golomb, F. Pieruzzi, and H. R. Keiser Pulmonary and Renal Neutral Endopeptidase EC 3.4.24.11 in Rats With Experimental Heart Failure Hypertension, June 1, 1995; 25(6): 1178 - 1184. [Abstract] [Full Text] |
||||
![]() |
J. G. Motwani, C. C. Lang, G. Cramb, and A. D. Struthers Natriuretic Response to Neutral Endopeptidase Inhibition Is Blunted by Enalapril in Healthy Men Hypertension, April 1, 1995; 25(4): 637 - 642. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |